Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M)Simona Di Giambenedetto, Daniela Francisci, Pierangelo Chinello et al.|Journal of Antimicrobial Chemotherapy|2016Cited by 75
Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patientsGianmaria Baldin, Simona Di Giambenedetto, Arturo Ciccullo et al.|International Journal of Antimicrobial Agents|2019Cited by 55
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trialMassimiliano Fabbiani, Roberta Gagliardini, Nicoletta Ciccarelli et al.|Journal of Antimicrobial Chemotherapy|2018Cited by 33
Simplification to atazanavir/ritonavir plus lamivudine versus maintaining atazanavir/ritonavir+2NRTIs in virologically suppressed HIV-infected patients: 96-week data of the ATLAS-M trialRoberta Gagliardini, Andrea De Luca, Massimiliano Fabbiani et al.|Unknown|2016Cited by 11
Reduced probability of improving viro‐immunological state in subjects with vertical transmission of HIV reaching adult age: A multicenter retrospective cohort studyFrancesca Pennati, Emanuele Focà, Stefano Calza et al.|Immunity Inflammation and Disease|2023Cited by 4